The role of radiotherapy (RT) in diffuse large B-cell lymphomas with advanced disease is unclear. In this retrospective study, 2 cooperating university hospitals in Western Norway had different practices in use of RT, but similar patient characteristics and chemotherapy. RT to a residual mass after chemotherapy, in low-intermediate risk groups with advanced disease, was associated with improved cancer-specific and overall survival. Background: The role of consolidative radiotherapy (RT) in advanced diffuse large B-cell lymphoma (DLBCL) is not established. Patients and Methods: In a population-based retrospective analysis of patients with DLBCL in Western Norway during 2003 to 2008, 170 consecutive patients admitted to Haukeland University Hospital (HUS) and 94 to Stavanger University Hospital (SUS) were included. The mean age was 64 years (range, 17-95 years), 147 patients (56%) were male, 80 patients (30%) had stage I/II, 126 patients (48%) stage III/IV, and 57 patients (22%) had primary extranodal disease. Results: There were no differences between hospitals in patient characteristics, use of rituximab, number of chemotherapy courses or cumulative doses, or in distribution of response categories after chemotherapy. The use of RT was significantly different: 17 patients (23%) received RT at SUS and 92 patients (65%) at HUS (P < .001). For 219 patients with International Prognostic Index (IPI) score of 0 to 3, 5-year cancer-specific survival (CSS) was 67% at SUS and 81% at HUS (P ¼ .012). For 73 patients with complete response after chemotherapy there were no differences in survival between patients with and without RT. For 138 patients with any residual mass after chemotherapy, there were highly significant differences in favor of receiving RT (n ¼ 81) versus no RT (n ¼ 57): 5-year CSS 89% versus 69% (P < .001), and 5-year overall survival 82% versus 59% (P ¼ .005). The effect of RT on residual mass was evident in most subgroups, mainly in low to intermediate risk, but not in high-risk (IPI 4-5) patients. Conclusion: With the limitations of a retrospective study, these data suggest that consolidative RT might improve survival in DLBCL patients with a residual mass after chemotherapy, also in advanced disease.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. 1 The prognosis of DLBCL has improved considerably with additional use of the anti-CD20 monoclonal antibody rituximab with chemotherapy. The treatment approach has been summarized in review articles. 2, 3 In DLBCL stage I to II disease, the role of consolidation radiotherapy (RT) after limited chemotherapy has been investigated in several randomized trials, 4, 5 and the additional use of rituximab with chemotherapy followed by RT in a phase II study. 6 Several retrospective studies of stage I to II DLBCL have suggested outcome benefit for the use of RT. [7] [8] [9] Thus, RT might be used as an integral part of the treatment of localized stage I to II disease, however still with controversies. 10, 11 The role of RT in advanced DLBCL (stages III to IV) has not been clearly established from randomized trials, although several retrospective or prospective studies have suggested a role for consolidation RT. [12] [13] [14] [15] [16] [17] [18] [19] In recent review articles on the role of RT in DLBCL, consolidation RT was suggested to be beneficial at achieving local disease control and improving overall outcomes, especially in specific clinical settings such as initially bulky disease, in advanced disease with residual masses after chemotherapy, or with extranodal bone involvement. 20, 21 All lymphoma treatment in Norway is organized through the governmental hospitals in the 4 Regional Health Care Trusts. In Western Norway, serving a population of 1.1 million, 2 hospitals, Stavanger University Hospital (SUS) and Haukeland University Hospital (HUS), are responsible for the management, in cooperation with local hospitals in Haugesund and Førde. The patients are treated according to national lymphoma guidelines. As quality assurance of patient management, we, in collaboration performed a retrospective study of all patients registered with DLBCL in the Western part of Norway during the time period 2003 to 2005. Because the initial analyses showed a discrepancy in outcome between patients treated at the 2 institutions, an additional cohort of the patients treated in 2006 to 2008 was investigated, and a thorough analysis of the material was done, in an attempt to identify any differences in practice that could explain the findings. The patient characteristics, use of chemotherapy, and distribution of response categories were very similar between the 2 hospitals, SUS and HUS, whereas there proved to be a highly significant difference in use of RT, especially to residual masses after chemotherapy in stage III to IV disease. This made the data suitable for investigating the possible role of RT in DLBCL treatment.
Patients and Methods
This population-based retrospective study was approved by the Regional Ethics Committee in Norway (3.2006.1577, and 2011/ 855) , and by the Norwegian Social Science Data Services (14, 866) . All patients alive received written information, with passive consent.
In 2009 and 2011, we retrospectively reviewed the medical records of all DLBCL patients admitted to the 2 university hospitals (SUS and HUS), for the time period 2003 to 2008. The database was updated in April 2015.
Among 264 patients included, 246 had histologically verified DLBCL, 4 Tecell-rich DLBCL, 7 primary mediastinal DLBCL, and 7 follicular lymphoma grade 3B according to the World Health Organization classification. 22 Patients with transformed low-grade lymphoma, Burkitt lymphomas, or primary central nervous system lymphomas were not included. The study period was before positron emission tomography (PET)/computed tomography (CT) was generally available in the Western part of Norway, and included the time period when rituximab was implemented as standard treatment in addition to use of chemotherapy (2003) (2004) .
Patient characteristics were determined from the medical records as interpreted by the treating physicians and radiologists. These characteristics included presence of bulky disease, staging on the basis of the Ann Arbor classification, 23 including CT scans and bone marrow biopsy, International Prognostic Index (IPI) scores, 24 and response categories. 25 We did not undertake a formal review of all CT scans before, during, and after the end of chemotherapy. Thus, as judged retrospectively, the interpretations of either complete response (CR) or CR unconfirmed (CRu) might, to some extent, vary between physicians. To investigate the role of RT with regard to residual masses after chemotherapy, we categorized patients as either CR versus patients with "any residual mass." The latter included partial response (PR) and CRu, and also more uncertain residual masses such as relatively small residual masses unchanged in size over time (ie, between 3 and 6 chemotherapy courses), residual masses with no signs of vital lymphoma on biopsy, or residual masses negative according to PET/CT after chemotherapy. The chemotherapy regimens used were rituximab with cyclophosphamide, doxorubicin, vincristine, (etoposide), and prednisolone (R-CHO(E)P)-or CHO(E)P-based (the latter in 2003, before rituximab with chemotherapy was implemented as standard therapy). Patients received consolidation RT at the discretion of the treating physician. When administered, consolidation RT was generally started 3 to 4 weeks after chemotherapy was finished, usually given to 1 or sometimes 2 target volumes, usually as conformal RT with photon beams, and with a fraction dose of 1.8 Gy to a total of 36 Gy.
Statistical Analyses
Categorical characteristics were compared between patients with or without RT as part of the treatment, using c 2 statistics.
Continuous variables were assessed using independent t tests. Survival was calculated using the KaplaneMeier product limit method, with P values from the log-rank test. Survival was defined as the time from the date of start of lymphoma treatment, to the date of event (death) or date of last follow-up (censored). For cancerspecific (ie, lymphoma-specific) survival (CSS) events were defined as death from lymphoma, or death from any other cause with lymphoma. Overall survival (OS) was defined as death from any cause. All probability values were 2-sided. Statistics were performed using the SPSS version 24 (IBM Corp, Armonk, NY).
Results
An overview of the study is shown in Figure 1 . Patient and treatment characteristics for the patient cohort are summarized in the upper part of Figure 1 , also for hospitals SUS and HUS, with the resulting hypothesis that the observed difference in 5-year CSS between hospitals could be ascribed to a highly significant difference in use of consolidative RT. The mid part of Figure 1 shows a summary of patient and treatment characteristics, and survival, for patients with or without RT in primary treatment, also according to response status after chemotherapy. The lower part of Figure 1 is focused on patients with stage II/III/IV with a residual mass after chemotherapy, with the aim of identifying patients with a possible benefit from consolidative RT. ). An IPI score of 0 or 1 was detected in 111 patients (42%), IPI score of 2 or 3 in 109 patients (41.3%), and IPI score of 4 or 5 in 41 patients (15.5%). There were no significant differences between the 2 hospitals, SUS and HUS, for any of these patient characteristics.
The Patient Cohort
Among 260 patients who received chemotherapy, the mean number of chemotherapy courses was 5.78 (range, 1-10). The chemotherapy regimens were R-CHO(E)P-based in 200 patients (76%) and CHO(E)P-based in 55 (21%), whereas 5 patients received other chemotherapy regimens, and 4 patients aged older than 85 years did not want chemotherapy. During the a Of 264 patients included in the study, 211 were included in analyses with consolidative RT versus without RT in primary treatment. Twenty-five patients had primary PD, and 24 died during the chemotherapy period; these 49 patients were excluded (not "at risk" for consolidative RT). In addition, 4 patients of age older than 85 years who did not want chemotherapy were excluded. The 138 patients with residual masses after chemotherapy included 22 patients with PR and 116 patients with CR unconfirmed, the latter also comprising 46 patients with "uncertain" residuals either biopsynegative (n ¼ 17), small residuals unchanged over time during chemotherapy (n ¼ 25), or PET-negative after chemotherapy (n ¼ 4). b P from independent t tests. Radiotherapy in Diffuse Large B-cell Lymphoma, A Retrospective Study chemotherapy period, 24 patients (9.2%) died, and 25 patients (9.6%) had primary progressive disease (PD).
There were no significant differences in number of chemotherapy courses, in cumulative doses (mg/m 2 ) of cyclophosphamide or doxorubicin, or in use of rituximab, between the 2 hospitals (SUS and HUS; data not shown).
Excluding 4 patients not given chemotherapy, response evaluation after end of chemotherapy was assessed as CR in 73 of 260 patients (28.1%). "Any residual mass" was detected in 138 patients (53.1%), including 22 patients (8.5%) with PR, and 116 patients (44.6%) with CRu. The latter CRu category also included 46 patients with uncertain residual masses, comprising 17 patients with residual mass but without histologic evidence of lymphoma on biopsy, 4 patients with residual mass but negative PET/CT scan, and 25 relatively small residuals with no change in size over time during the chemotherapy period (eg, between 3 and 6 courses). There were no differences between broad response categories between the 2 hospitals (SUS and HUS; data not shown).
Although there were no differences between hospitals SUS and HUS for patient characteristics, use of chemotherapy or rituximab, or response categories after chemotherapy, there were highly significant differences in use of consolidative RT. For the analyses of consolidative RT, patients with PD or patients having died during the chemotherapy period were excluded, because they were not "at risk" for receiving consolidative RT. Among 74 patients at SUS, 17 (23.0%) received consolidative RT, whereas among 141 patients at HUS, 92 (65.2%) received RT (P < .001). In pooled data from the 2 hospitals, RT in the primary treatment was given to 109 of 215 patients (50.7%), and the indications were as follows: in 50 patients (23.3%) to a residual mass/initially bulky disease, in 33 patients (15.3%) to extranodal disease, and in 23 patients (10.7%) as initially planned treatment in stage I to II after chemotherapy. In addition, 3 patients who did not want chemotherapy received palliative RT.
Outcome. The median follow-up (time interval between start of lymphoma treatment and time of death or last contact) was 5.5 years (range, 0.0-11.8 years) for all 264 patients. Among 139 patients alive at censoring, the median follow-up was 7.3 years (range, 1.8-11.8 years), and in 125 patients who died before April 2015, the median follow-up was 1.5 years (range, 0.0-11.4 years).
For all 264 patients, 5-year OS was 62% (standard error [SE], 3%). The 5-year CSS was 69% (SE, 3%), with no significant difference between the 2 hospitals (64% at SUS vs. 72% at HUS; P ¼ .14). There was a significant difference in CSS between the 2 hospitals for the 219 patients with IPI score 0 to 3 (5-year CSS 67% at SUS vs. 81% at HUS; P ¼ .012). Among 41 patients with IPI score 4 to 5, there were no differences in 5-year CSS (40% at SUS vs. 39% at HUS; P ¼ .58), or in 5-year OS (30% at SUS vs. 39% at HUS; P ¼ .33).
With Versus Without Radiotherapy
Patient Characteristics According to Consolidative RT. For analyses including consolidative RT, patients with PD (n ¼ 25) or patients who died during the chemotherapy period (n ¼ 24) were excluded. In addition, 4 patients aged 85 to 89 years who refused chemotherapy were excluded. Thus 211 patients were included in analyses with or without RT, comprising 138 patients with a residual mass after chemotherapy, and 73 patients with CR.
For 73 patients with CR, there were no significant differences between those not receiving RT and those receiving RT, for any of the patient characteristics (Table 1) , but with a trend for difference in distribution of stage (Table 1) .
Among the 138 patients with any residual mass after chemotherapy, the groups who received RT (n ¼ 81), or did not receive RT (n ¼ 57), were well balanced regarding age, IPI scores (0-3 vs. 4-5), bulky disease, or elevated LDH level. There was a higher proportion of women, and lower proportions of patients with stage III to IV and with B-symptoms, in those who received RT ( Table 1) .
In a comparison of chemotherapy treatment characteristics, with or without RT, analyses were limited to stages II/III/IV to make meaningful comparisons (Table 1 ). In patients with CR, as well as in patients with a residual mass after chemotherapy, there were no significant differences between the "no RT" and "with RT" groups, either in mean doxorubicin or cyclophosphamide cumulative doses, or in the use of rituximab, or in the mean number of chemotherapy courses (Table 1) .
Outcome According to Consolidative Radiotherapy. Among 211 patients (all stages I-IV and PE, and all response categories, but excluding PD and patients who died during the chemotherapy period) 5-year CSS was 82% in those who did not receive RT and 89% in those who received consolidative RT (P ¼ .044; Figure 2A) .
For the 73 patients with CR after chemotherapy, we found no significant differences without RT versus with RT, in 5-year CSS (98% vs. 92%), or in 5-year OS (85% vs. 92%), respectively ( Figure 2B , Table 1 ).
In contrast, in the 138 patients with any residual mass after chemotherapy, there were highly significant differences in outcome between those not who did not receive RT and those who did receive consolidative RT. Among 57 patients who did not receive RT, 5-year CSS was 69%, whereas among 81 patients who received RT 5-year CSS was 89% (P < .001; Figure 2C , Table 1 ). Correspondingly, 5-year OS was 59% in those who did not receive RT and 82% in those who did receive RT (P ¼ .005; Figure 2D , Table 1 ).
Stage II/III/IV Disease With a Residual Mass
The difference in use of consolidative RT between the 2 hospitals SUS and HUS was most evident for patients with stages II/III/IV disease and a residual mass after chemotherapy.
This group comprised 94 patients, and their characteristics, with or without consolidative RT, are shown in Supplemental Table 1 in the online version. There were no significant differences for mean age, sex, stage (II vs. III vs. IV), IPI score (0-2 vs. 3-5), bulky disease, elevated LDH (< 300 vs. > 300), number of chemotherapy courses, or doxorubicin or cyclophosphamide cumulative doses. There was a lower frequency of B-symptoms in those who received RT (see Supplemental Table 1 Figure 2F (OS), with a 5-year CSS of 88% in those who received RT versus 68% in those who did not receive RT (P ¼ .003; Figure 2E , Table 2 ). Five-year OS was 84% in those who received RT, versus 57% in those who did not receive RT (P ¼ .014; Figure 2F ).
Of these 94 stage II/III/IV patients, 60 had a clear residual mass (PR or CRu). In these 60 patients (ie, excluding the 34 with "uncertain" residual mass), 41 patients (68%) received consolidative RT. At time of censoring, cancer-specific death had occurred in 5 of 41 patients (12%) given RT, and in 10 of 19 patients (53%) not given RT (P < .001; Figure 2G ), with the corresponding plot for OS shown in Figure 2H .
In 34 of the 94 patients, the CRu residual mass were interpreted by the treating physician as uncertain; of these only 3 patients (9%) received RT. These 34 patients included 12 with biopsy-negative residual mass, 19 with small residual mass unchanged over time during chemotherapy, and 3 patients with PET-negative residual mass. Relapse occurred in 12 (35%) of these 34 patients, including 4 with biopsy-negative residual mass. At censoring, cancer-specific death had occurred in 10 of 34 patients (29%), including 4 Radiotherapy in Diffuse Large B-cell Lymphoma, A Retrospective Study deaths after 5 years of follow-up. Of these 10 patients with lymphoma-specific death, 9 did not receive consolidative RT. Five-year CSS for these 94 patients with stage II/III/IV disease and a residual mass, with or without RT, and according to subgroup, is shown in Table 2 . There was significantly improved CSS in patients who received consolidative RT across most subgroups. Generally, except for high-risk patients with IPI score of 4 to 5, 5-year CSS was approximately 20% higher in the groups that received consolidative RT ( Table 2 ). The benefit in 5-year CSS with RT was most evident for the low-intermediate risk groups (Table 2 ). In the high-risk patients with IPI score 4 to 5, 5-year CSS was 86% in those who received RT compared with 79% for those who did not receive RT (P ¼ .47).
In these 94 patients, we investigated the prognostic effect of the other clinical variables for CSS (see Supplemental Table 2 in the online version) and OS (see Supplemental Table 3 in the online version). There were no significant differences in 5-year CSS for subgroups within age (< 65 vs. 65 years), sex, stage (II vs. III vs. IV), IPI score (0 to 3 vs. 4 to 5), bulky disease, or LDH (< 300 U/L vs. 300), or within cyclophosphamide (< 4500 vs. > 4500 mg/m 2 ) or doxorubicin (< 300 vs. > 300 mg/m 2 ) cumulative doses (see Supplemental Table 2 in the online version). For 5-year OS, there was as expected a significant effect for age, otherwise no significant differences for subgroups within the other clinical variables (see Supplemental Table 3 in the online version).
Discussion
In this retrospective study comprising virtually all adult patients with DLBCL in the Western part of Norway during the time interval 2003 to 2008, patient and treatment characteristics were very similar between the 2 university hospitals SUS and HUS, except for the use of RT during primary treatment, especially to a residual mass after chemotherapy and most evident in stage III to IV disease.
When the complete patient cohort was analyzed, there was no significant difference in 5-year CSS between hospitals. However, when the high-risk patients (IPI 4-5) were excluded, a significant difference in CSS was seen in favor of HUS. There were no significant differences between hospitals for clinical prognostic factors, and further no differences in use of rituximab, in number of chemotherapy courses, or in doxorubicin and cyclophosphamide cumulative doses. Thus, we hypothesized that the observed improved cancer-specific (ie, lymphoma-specific) survival at HUS, for low-to intermediate-risk DLBCL patients could be explained by a highly significant difference in the use of consolidative RT to a residual mass after chemotherapy.
This study was population-based, with all patients admitted to the 2 hospitals in the 6-year period included. The hospitals followed the same national lymphoma guidelines for use of chemotherapy, with similar treatment characteristics for chemotherapy, but with a very different use of RT during primary treatment. Of note, use of RT and especially to DLBCL in stages III to IV, was not specified in detail in national lymphoma treatment programs, thus the use of RT in this clinical setting became highly dependent on local traditions and preferences. Although the use of chemotherapy and rituximab usually is described thoroughly in national and international protocols for clinical studies of DLBCL with advanced disease, the use of RT is often only briefly mentioned.
The main limitation of this study is the retrospective design. Response categories have been reported as interpreted by the treating physician according to the patient files. There might be differences in interpretations between radiologists and individual treating physicians. This could be a limitation of the study, however, it reflects decision-making in daily practice outside of formal clinical studies.
We focused on the specific group of patients with DLBCL stages II/III/IV with any residual mass after chemotherapy, with the aim to elucidate use of consolidative RT in this group. To be able to analyze the distribution of patient and treatment characteristics, Patients with CR after chemotherapy, primary extranodal disease, stage I disease, primary PD, or death during chemotherapy, were excluded. Of 44 stage II/III/IV patients receiving consolidative RT, 40 (91%) had RT to a residual mass after chemotherapy/initial bulk (including 28 patients in stage III-IV, and 12 patients in stage II), and 4 patients (9%) had RT to extranodal sites. Eleven of 12 patients in stage II receiving RT had 6 or more chemotherapy courses (ie, RT was not given as part of initially planned treatment after limited 3-4 courses chemotherapy). One patient had missing data for Bsymptoms, 1 for LDH, and 1 for IPI score. Abbreviations: CRu ¼ CR unconfirmed; CSS ¼ cancer-specific (ie, lymphoma-specific) survival; DLBCL ¼ diffuse large B-cell lymphoma; IPI ¼ International Prognostic Index; LDH ¼ lactate dehydrogenase; PET ¼ positron emission tomography; RT ¼ radiotherapy; SE ¼ standard error. a P from KaplaneMeier analyses with log-rank test. b The 94 stage II/III/IV patients with a residual mass after chemotherapy comprised 10 patients with PR, and 84 patients with CRu including 34 patients with "uncertain" residuals either biopsy negative, unchanged in size over time during chemotherapy, or PET-negative after chemotherapy. c Lactate dehydrogenase normal range, 105 to 205 U/L.
possible prognostic factors, CSS and OS, and effects of consolidative RT specifically to this group, patients with no residual mass (CR) were excluded. DLBCL stage I and PE disease were excluded because in these patients RT might often be initially planned as part of the treatment strategy, and therefore be less dependent on the response status after chemotherapy. Patients with primary PD and patients who died during the chemotherapy period were excluded because these were not "at risk" for consolidative RT.
In patients with a clear residual mass (PR or CRu), there were highly significant and surprisingly large differences of approximately 20% (varying from 15% to 40% in subgroups) in CSS in favor of consolidative RT. These differences in survival could not be explained by uneven distribution of clinical prognostic factors between the groups who did and did not receive RT, by differences in chemotherapy courses, chemotherapy dose intensity, or by the use of rituximab. Thus, the data in this study, although limited by its retrospective design, strongly suggest a benefit of consolidative RT to a residual mass after chemotherapy.
Whether the group of patients with an "uncertain" residual mass could benefit from RT, remains elusive from this study. Only 3 patients (9%) of the 34 patients with "uncertain" residual mass received consolidative RT. Among the 31 patients with "uncertain" residual mass who did not receive consolidative RT, 5-year CSS was 84%. Four late lymphoma-specific deaths occurred after the 5-year follow-up, so during the complete follow-up a total of 9 lymphomaspecific deaths occurred, and the 8-year CSS was 64%. This contrasts to 90% 5-and 8-year CSS among 60 patients with clear residual masses given consolidative RT, and 41% 5-and 8-year CSS for patients with clear residual masses not receiving RT. Among the patients with "uncertain" residual mass, lymphoma relapse occurred in 4 of 12 patients with a negative biopsy after chemotherapy, in 7 of 19 patients with small residual mass unchanged in size during chemotherapy, and in 1 of 3 patients with negative PET imaging after chemotherapy. This could indicate that also patients with "uncertain" residual mass might benefit from consolidative RT.
Although to our knowledge no randomized study has been published on the role of RT in advanced DLBCL, several retrospective studies have addressed this issue. The role of consolidative RT after R-CHOP therapy was investigated in a retrospective study of 469 DLBCL patients among whom 60% had advanced disease, reporting a 5-year OS and progression-free survival (PFS) of 89% and 76% for stage III to IV patients treated with consolidative RT, versus 66% and 55% in those without RT. 18 Among 43 patients with residual masses according to CT scan but a negative PET image after chemotherapy who received RT, OS and PFS were comparable to that in patients who achieved a CR. However, in contrast to our present study, the authors also reported a significant benefit of RT in patients with a CR after chemotherapy.
18
A retrospective study performed before the rituximab era, in DLBCL stage III to IV patients with bulky or semibulky lesions in complete remission after chemotherapy, reported improved outcome in those who received consolidative RT. 15 Also addressing the role of consolidation RT in DLBCL stage III to IV with negative imaging after R-CHOP chemotherapy, consolidation RT (median 25 Gy) to involved sites was associated with improved in-field control and event-free survival, but with no difference in OS compared with those without RT. 17 In patients with no residual mass and CR to chemotherapy, we found no significant benefit from consolidative RT, for either CSS or OS. A study in elderly DLBCL patients compared the best arm of the RICOVER-60 trial (6 versus 8 cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive B-cell lymphomas), 26 with involved-field RT (36 Gy) to initial bulky or extranodal sites, to a cohort receiving the same chemotherapy without RT, and reported improved outcome with consolidative RT. 13 Use of RT to DLBCL in the rituximab era was investigated retrospectively in a large American study. 19 It included 841 patients;
35% received RT after ReCHOP-based chemotherapy, with improved 5-year OS and failure-free survival with RT compared with without RT. In the MabThera International Trial Group (MInT) study, young good-prognosis DLBCL patients with stages II to IV or bulky stage I were randomized to 6 CHOP with or without rituximab, and patients with bulky or extranodal disease received consolidative RT. 27 Indirect comparison of data from the MInT study with a similar patient population receiving either ReCHOP-21 or a more intensified chemotherapeutic regimen but without RT, 28 suggested better outcome and a possible beneficial effect of RT, underscoring the need for a randomized study. 27 The possible role of consolidation RT in DLBCL, also in advanced stage III to IV disease, has recently been discussed. 29 However, the role of RT in this clinical setting is still not established.
Our study was performed before PET/CT was generally available in Western Norway. Therefore, during the study time interval of 2003 to 2008 only a few patients had PET imaging at the end of chemotherapy, a procedure now routinely performed in most DLBCL patients. The current status of PET imaging in DLBCL has been reviewed. 30 The ability for PET/CT imaging to predict outcome at end of chemotherapy is supported by several retrospective studies, 31 and new criteria for response assessment using PET/CT imaging has eliminated the CRu category. 32, 33 In a retrospective study of 300 DLBCL patients, however, PET versus CT was evaluated for response characterization after chemotherapy. Seventy-three percent of the patients had received R-CHOP and none had RT. Five-year OS, disease-specific survival, and PFS were higher in patients with CR according to PET as well as CT imaging (85%, 87%, and 84%, respectively) than in patients with CR only according to PET imaging (66%, 71%, and 64%, respectively), and compared with those with residual disease according to PET and CT imaging (35%, 40%, and 42%, respectively). 34 Thus, the presence of a residual mass on CT scan, despite negative findings on PET imaging, was associated with inferior outcome, and the authors concluded that any residual mass after chemotherapy > 2 cm in diameter should be regarded with suspicion, and biopsy or consolidative RT should be considered. 34 Although in our study PET/CT imaging was only performed in a small percentage of patients, our data support the conclusions of that study showing an effect of a residual mass and advocating consideration of consolidative RT. A recent review on the use of RT in DLBCL in advanced stages, suggests that withholding consolidative RT in PET-based CRs is premature. 35 The late toxicity from RT has been recognized, especially for patients treated with large mediastinal fields. For younger patients with primary mediastinal DLBCL, efforts should focus on eliminating or optimizing radiation therapy because of possible late
Øystein Fluge et al
Clinical Lymphoma, Myeloma & Leukemia February 2018 -133 toxicity. In a phase II study, using the dose-adjusted etoposide, prednisolone, vincristin, cyclophosphamide, doxorubicin with rituximab regimen for primary mediastinal DLBCL, 5-year event-free survival was 93% and OS 97%, thus obviating the need for consolidative RT. 36 However, in most patients with DLBCL, with a mean age of approximately 65 years at diagnosis, and for example 1 residual mass after chemotherapy (eg, in the retroperitoneal area), the clinical effect of possible late toxicity is very different from the young patient with a bulky mediastinal tumor.
In the present study, we found a surprisingly large difference in survival in favor of RT in patients with advanced disease and a residual mass after chemotherapy. The absolute differences in OS and CSS were approximately 20%, and in univariate analyses evident across most subgroups except the high-risk (IPI score of 4-5) patient group. The traditional rationale for consolidative RT to residual masses after chemotherapy involves enhanced local lymphoma control by eradication of remaining clonogenic tumor cells through damage to DNA and permanent proliferative arrest. The relatively large difference in survival in favor of consolidative RT observed in this study, given to 1 or sometimes 2 target volumes, leads to the hypothesis that systemic antitumor effects could be activated from sequential multimodal immunochemotherapy followed by RT. Recently, the knowledge of biological mechanisms for inhibition and activation of immune responses to tumor cells, with the immune checkpoint inhibitor systems and the important role of tumor stroma, has increased rapidly. Increasing focus has also been attributed to immunogenic cell death (ICD) and the interaction between RT and tumor-specific adaptive immune responses operating also outside the radiation target volume. ICD involves a variant of apoptosis including release of damage-associated molecular patterns stimulating an adaptive tumor-specific immune response. 37 Doxorubicin, cyclophosphamide, and RT have been associated with induction of ICD and adaptive immune responses against dying cells. 38,39 A possible synergy of RT and immune checkpoint inhibitors has been suggested. 40 Thus, the surprisingly large survival benefit associated with consolidative RT in our study might also be influenced by an RT-associated ICD and enhanced adaptive antilymphoma immune response to primarily surviving lymphoma cells outside of the radiated volumes.
Conclusion
With the limitations of a retrospective study, the data in this study support accumulating data that indicate that consolidative RT might improve survival in patients with DLBCL of advanced stage with a residual mass after chemotherapy.
Clinical Practice Points
In patients with DLBCL, the role of RT is considered unclear, especially in advanced stages. In this retrospective, population-based study from 2 university hospitals in Western Norway, with similar patient and chemotherapy treatment characteristics, but very different use of RT, a difference in CSS was observed. In patients with CR (no residual mass) after chemotherapy, use of RT was not associated with improved outcome. In patients of stage II/III/IV with any residual mass after chemotherapy, the use of RT was associated with improved CSS and OS, most evident in low-and intermediate-risk groups, but not in high-risk (IPI score of [4] [5] 
